These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

124 related articles for article (PubMed ID: 39322226)

  • 21. The Validated Investigator Global Assessment for Atopic Dermatitis (vIGA-AD™): a clinical outcome measure for the severity of atopic dermatitis.
    Simpson EL; Bissonnette R; Paller AS; King B; Silverberg JI; Reich K; Thyssen JP; Doll H; Sun L; DeLozier AM; Nunes FP; Eichenfield LF
    Br J Dermatol; 2022 Oct; 187(4):531-538. PubMed ID: 35442530
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Baseline characteristics, disease severity and treatment history of patients with atopic dermatitis included in the German AD Registry TREATgermany.
    Heratizadeh A; Haufe E; Stölzl D; Abraham S; Heinrich L; Kleinheinz A; Wollenberg A; Weisshaar E; Augustin M; Wiemers F; Zink A; von Kiedrowski R; Hilgers M; Worm M; Pawlak M; Sticherling M; Fell I; Handrick C; Schäkel K; Staubach-Renz P; Asmussen A; Schwarz B; Bell M; Effendy I; Bieber T; Homey B; Gerlach B; Tchitcherina E; Stahl M; Schwichtenberg U; Rossbacher J; Buck P; Mempel M; Beissert S; Biedermann T; Weidinger S; Schmitt J; Werfel T;
    J Eur Acad Dermatol Venereol; 2020 Jun; 34(6):1263-1272. PubMed ID: 31721316
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Topical tacrolimus for atopic dermatitis.
    Cury Martins J; Martins C; Aoki V; Gois AF; Ishii HA; da Silva EM
    Cochrane Database Syst Rev; 2015 Jul; 2015(7):CD009864. PubMed ID: 26132597
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Tralokinumab Plus Topical Corticosteroids as Needed Provides Progressive and Sustained Efficacy in Adults with Moderate-to-Severe Atopic Dermatitis Over a 32-Week Period: An ECZTRA 3 Post Hoc Analysis.
    Silverberg JI; Adam DN; Zirwas M; Kalia S; Gutermuth J; Pinter A; Pink AE; Chiricozzi A; Barbarot S; Mark T; Tindberg AM; Weidinger S
    Am J Clin Dermatol; 2022 Jul; 23(4):547-559. PubMed ID: 35857179
    [TBL] [Abstract][Full Text] [Related]  

  • 25. AtopyReg
    Stingeni L; Chiricozzi A; Calzavara-Pinton P; Napolitano M; Peris K; Schena D; Patruno C; Rossi M; Foti C; Fargnoli MC; Corazza M; Ferrucci SM; Pigatto PD; Romanelli M; Fabbrocini G; Girolomoni G; Passante M; Romita P; Esposito M; Schettini N; Marzano AV; Tonini G; Marietti R; Casciola G; Argenziano G; Hansel K;
    Am J Clin Dermatol; 2024 Jan; 25(1):149-160. PubMed ID: 37725229
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Itching in Atopic Dermatitis: Patient- and Physician-reported Outcomes in the German Atopic Dermatitis Registry TREATgermany.
    Weisshaar E; Bentz P; Apfelbacher C; Haufe E; Heinrich L; Heratizadeh A; Abraham S; Harder I; Kleinheinz A; Wollenberg A; Schäkel K; Wiemers F; Ertner J; Augustin M; Wildberger J; Von Kiedrowski R; Worm M; Zink A; Effendy I; Asmussen A; Pawlak M; Sticherling M; Hilgers M; Handrick C; Quist S; Schwarz B; Bell M; Staubach-Renz P; Hong-Weldemann SH; Homey B; Brücher JJ; Weidinger S; Werfel T; Schmitt J;
    Acta Derm Venereol; 2023 Jan; 103():adv00854. PubMed ID: 36688701
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Associations Between Shower and Moisturizing Practices with Atopic Dermatitis Severity: A Prospective Longitudinal Cohort Study.
    Rakita U; Kaundinya T; Silverberg JI
    Dermatitis; 2023; 34(5):425-431. PubMed ID: 36917546
    [No Abstract]   [Full Text] [Related]  

  • 28. Baricitinib improves symptoms in patients with moderate-to-severe atopic dermatitis and inadequate response to topical corticosteroids: patient-reported outcomes from two randomized monotherapy phase III trials.
    Reich K; DeLozier AM; Nunes FP; Thyssen JP; Eichenfield LF; Wollenberg A; Ross Terres JA; Watts SD; Chen YF; Simpson EL; Silverberg JI
    J Dermatolog Treat; 2022 May; 33(3):1521-1530. PubMed ID: 33222559
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Early and Sustained Improvements in Symptoms and Quality of Life with Upadacitinib in Adults and Adolescents with Moderate-to-Severe Atopic Dermatitis: 52-Week Results from Two Phase III Randomized Clinical Trials (Measure Up 1 and Measure Up 2).
    Silverberg JI; Gooderham MJ; Paller AS; Deleuran M; Bunick CG; Gold LFS; Hijnen D; Calimlim BM; Lee WJ; Teixeira HD; Hu X; Zhang S; Yang Y; Grada A; Platt AM; Thaçi D
    Am J Clin Dermatol; 2024 May; 25(3):485-496. PubMed ID: 38528257
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Burden of Atopic Dermatitis in the United States: Analysis of Healthcare Claims Data in the Commercial, Medicare, and Medi-Cal Databases.
    Shrestha S; Miao R; Wang L; Chao J; Yuce H; Wei W
    Adv Ther; 2017 Aug; 34(8):1989-2006. PubMed ID: 28707285
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Assessment of clinical signs of atopic dermatitis: a systematic review and recommendation.
    Schmitt J; Langan S; Deckert S; Svensson A; von Kobyletzki L; Thomas K; Spuls P;
    J Allergy Clin Immunol; 2013 Dec; 132(6):1337-47. PubMed ID: 24035157
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Placebo responses in randomized controlled trials for systemic therapy in atopic dermatitis: A systematic review and meta-analysis.
    Lee HH; Patel KR; Rastogi S; Singam V; Vakharia PP; Chopra R; Silverberg JI
    J Am Acad Dermatol; 2020 Jan; 82(1):62-71. PubMed ID: 31202874
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Attentiveness and mental health in adolescents with moderate-to-severe atopic dermatitis without ADHD.
    Paller AS; Gonzalez ME; Barnum S; Jaeger J; Shao L; Ozturk ZE; Korotzer A
    Arch Dermatol Res; 2024 Jul; 316(8):497. PubMed ID: 39080094
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Baricitinib provides rapid and sustained improvements in absolute EASI and SCORAD outcomes in adults with moderate-to-severe atopic dermatitis.
    Thyssen JP; Bieber T; Kleyn CE; Nosbaum A; Grond S; Petto H; Riedl E; Wollenberg A
    J Dermatolog Treat; 2023 Dec; 34(1):2216322. PubMed ID: 37345379
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Comparison of Patient-Oriented Eczema Measure and Patient-Oriented Scoring Atopic Dermatitis vs Eczema Area and Severity Index and other measures of atopic dermatitis: A validation study.
    Silverberg JI; Lei D; Yousaf M; Janmohamed SR; Vakharia PP; Chopra R; Chavda R; Gabriel S; Patel KR; Singam V; Kantor R; Hsu DY
    Ann Allergy Asthma Immunol; 2020 Jul; 125(1):78-83. PubMed ID: 32199977
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Efficacy and Safety of Dupilumab Treatment with Concomitant Topical Corticosteroids in Children Aged 6 Months to 5 Years with Severe Atopic Dermatitis.
    Paller AS; Pinter A; Wine Lee L; Aschoff R; Zdybski J; Schnopp C; Praestgaard A; Bansal A; Shumel B; Prescilla R; Bastian M
    Adv Ther; 2024 Mar; 41(3):1046-1061. PubMed ID: 38194047
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Validation of five patient-reported outcomes for atopic dermatitis severity in adults.
    Silverberg JI; Margolis DJ; Boguniewicz M; Fonacier L; Grayson MH; Ong PY; Fuxench ZC; Simpson EL
    Br J Dermatol; 2020 Jan; 182(1):104-111. PubMed ID: 30972740
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Baseline Demographics, Comorbidities, Treatment Patterns and Burden of Atopic Dermatitis in Adults and Adolescents from the GLOBOSTAD Long-Term Observational Study.
    Calzavara-Pinton P; Čelakovská J; Lapeere H; Holzer G; Al-Ahmad M; Chu CY; Ferrucci SM; Kataoka Y; Rossi M; Fomina DS; Chung WH; Tzellos T; Fougerousse AC; Wu J; Ardeleanu M; Ozturk ZE
    Adv Ther; 2023 Dec; 40(12):5366-5382. PubMed ID: 37801232
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Long-term Effectiveness and Safety of Upadacitinib for Atopic Dermatitis in a Real-world Setting: An Interim Analysis Through 48 Weeks of Observation.
    Chiricozzi A; Ortoncelli M; Schena D; Gori N; Ferrucci SM; Babino G; Napolitano M; Fargnoli MC; Stingeni L; Rossi M; Romanelli M; Balestri R; Pellegrino M; Parodi A; Bertoldi AM; Palazzo G; Antonelli F; Pitino A; Tripepi G; Fabbrocini G; Balato A; Marzano AV; Girolomoni G; Ribero S; Peris K
    Am J Clin Dermatol; 2023 Nov; 24(6):953-961. PubMed ID: 37322324
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Abrocitinib, tralokinumab and upadacitinib for treating moderate-to-severe atopic dermatitis.
    Edwards SJ; Karner C; Jhita T; Barton S; Marceniuk G; Yiu ZZN; Wittmann M
    Health Technol Assess; 2024 Jan; 28(4):1-113. PubMed ID: 38343072
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.